RESEARCH ARTICLE


Recombinant Production and Molecular Docking Studies of Casoplatelin, a Bioactive Peptide



Ragothaman M. Yennamalli1, 2, Pulkit Anupam Srivastava3, Sheena D. Sarswati3, Vijay Kumar Garlapati3, *
1 Department of Microbial Technology, School of Biological Sciences, Madurai Kamaraj University, Madurai-625021, India
2 Department of Bioinformatics, School of Chemical and Biotechnology,SASTRA University,Thanjavur-613401, Tamil Nadu, India
3 Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat -173234, Himachal Pradesh, India


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 4050
Abstract HTML Views: 1658
PDF Downloads: 1064
Total Views/Downloads: 6772
Unique Statistics:

Full-Text HTML Views: 1727
Abstract HTML Views: 790
PDF Downloads: 735
Total Views/Downloads: 3252



Creative Commons License
© 2020 Yennamalli et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat -173234, Himachal Pradesh, India; Tel: +91 1792 239288; Fax: +91 1792 245362; E-mail: shanepati@gmail.com


Abstract

Background:

Bioactive peptides from κ-casein have immense therapeutic potential as prophylactic formulations. Among these, casoplatelin is a κ-casein derived bioactive peptide with anti-thrombotic activities.

Aim:

Herein, we report the production of casoplatelin in an E. coli expression system (using a pBAD vector) and show in silico modeling of its interactions.

Methods:

A synthetic DNA construct encoding casoplatelin was designed with pepsin cleavage sites before and after the synthetic construct to allow the release of the peptide from the pro-peptide.

Results:

A novel recombinant approach was demonstrated for the production of casoplatelin, and anti-platelet aggregation activities of the product were confirmed. Also, casoplatelin structures were characterized in silico and then implemented to determine potential structural interactions with fibrinogen.

Conclusion:

The present study showcases the recombinant approach for biopeptide production and its interaction with fibrinogen through in silico approach.

Keywords: Casoplatelin, Bioactive peptide, Cloning, Molecular docking, Anti-thrombotic activity, Fibrinogen.